This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can indicate recurrence earlier than imaging examination, and explore the feasibility of guiding adjuvant therapy after curative treatment based on this model.
Male or female patients aged 18-75 years;
Preoperative imaging examination diagnosed hepatocellular carcinoma (BCLC) stage 0 / stage A/stage B, eligible for radical surgery;
ECOG physical status score is 0-1;
Child-Pugh score is 5-6 points (Level A);
Patient can't provide blood samples for ctDNA testing;
Patient with two or more types of tumors at the same time;
Non-primary liver lesions;
Pregnant or lactating women;